Loading...
XSHG
688076
, Last price  
Name

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:688076 chart
P/E
—
P/S
—
EPS
1.56
Vol. 1Y
—
Shs. 5Y
6.98%
Rev. 5Y
27.93%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.94b
+19.57%
008,777,2468,509,227228,867,458255,527,350371,530,569566,872,462643,869,464651,291,7061,033,548,0781,624,801,8841,942,799,144
Net income
332m
-17.80%
-13,635,899-25,157,141-30,153,957-74,797,49141,929,34143,908,45148,610,498123,441,591115,388,359129,106,569162,936,111404,389,996332,418,681
CFO
681m
+70.26%
43,671,70768,176,7540-21,951,56011,110,07096,057,44346,135,933141,381,334180,746,19929,292,086350,213,817400,116,077681,242,898
Dividend
Jun 12, 20260.35 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.
IPO date
May 20, 2021
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT